Saturday 31 October 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
62.55
1.16
+1.89%
Follow BMY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 46.63% | 38.75% | 40.43% | 33.74% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 7 | 8 | 7 | |
| 10.18% | 8.13% | 7.72% | 6.34% | ||
ROIC |
13.69% | 11.09% | 11.01% | 9.83% | |
Return on Tangible Assets |
52.41% | 46.31% | 52.19% | 40.69% | |
Average Days of Receivables |
78.31 | 70.53 | 86.44 | 86.79 | |
Free Cash Flow per Share |
5.60 | 5.84 | 6.32 | 7.52 | |
Free Cash Flow |
11,440.00 | 11,908.00 | 12,845.00 | 15,302.00 | |
Capital Expenditures |
(1,342.00) | (1,398.00) | (1,311.00) | (1,319.00) | |
| Other line items | |||||
Cash ROIC |
14.95% | 15.87% | 17.29% | 18.20% | |
Accounts Receivable Turnover |
4.48 | 4.81 | 4.35 | 4.28 | |
Accounts Payable Turnover |
3.06 | 3.48 | 3.88 | 3.78 | |
Inventory Turnover |
5.36 | 5.28 | 5.31 | 4.81 | |
Average Days of Payables |
103.40 | 107.89 | 93.63 | 106.82 | |
Days of Inventory on Hand |
68.06 | 70.23 | 70.45 | 68.71 | |
Tax Rate |
(0.22) | (0.24) | (0.24) | (0.25) | |
Research and Development Expense of Revenue |
21.80% | 21.33% | 20.65% | 21.98% | |
Selling, General and Administrative Expense of Revenue |
15.07% | 15.06% | 15.08% | 15.04% | |
Share Based Compensation of Revenue |
1.12% | 1.14% | 1.15% | 1.12% | |
Operating CF/Net income |
1.38 | 1.83 | 2.01 | 2.75 | |
Depreciation/Fixed assets |
0.41 | 0.47 | 0.53 | 0.67 | |
Capex/Depreciation |
(0.42) | (0.39) | (0.33) | (0.27) | |
Revenue per Share |
24.09 | 23.79 | 23.69 | 23.59 | |
Operating CF per Share |
6.26 | 6.53 | 6.96 | 8.16 | |
Capex per Share |
(0.66) | (0.69) | (0.64) | (0.65) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |
Columns are period end dates